Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF vs ETV in HBV-related compensated cirrhosis
NCT04196998Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tenofovir alafenamide in hepatitis B (HBV) and Liver cirrhosis (LC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Incidence of decompensated cirrhosis at 144 weeks. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04196998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196998.